Cargando…
A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design
The irreversible inhibition of the main protease of SARS-CoV-2 by a Michael acceptor known as N3 has been investigated using multiscale methods. The noncovalent enzyme–inhibitor complex was simulated using classical molecular dynamics techniques and the pose of the inhibitor in the active site was c...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179461/ https://www.ncbi.nlm.nih.gov/pubmed/34163622 http://dx.doi.org/10.1039/d0sc04978f |
_version_ | 1783703786680745984 |
---|---|
author | Ramos-Guzmán, Carlos A. Ruiz-Pernía, J. Javier Tuñón, Iñaki |
author_facet | Ramos-Guzmán, Carlos A. Ruiz-Pernía, J. Javier Tuñón, Iñaki |
author_sort | Ramos-Guzmán, Carlos A. |
collection | PubMed |
description | The irreversible inhibition of the main protease of SARS-CoV-2 by a Michael acceptor known as N3 has been investigated using multiscale methods. The noncovalent enzyme–inhibitor complex was simulated using classical molecular dynamics techniques and the pose of the inhibitor in the active site was compared to that of the natural substrate, a peptide containing the Gln–Ser scissile bond. The formation of the covalent enzyme–inhibitor complex was then simulated using hybrid QM/MM free energy methods. After binding, the reaction mechanism was found to be composed of two steps: (i) the activation of the catalytic dyad (Cys145 and His41) to form an ion pair and (ii) a Michael addition where the attack of the Sγ atom of Cys145 to the Cβ atom of the inhibitor precedes the water-mediated proton transfer from His41 to the Cα atom. The microscopic description of protease inhibition by N3 obtained from our simulations is strongly supported by the excellent agreement between the estimated activation free energy and the value derived from kinetic experiments. Comparison with the acylation reaction of a peptide substrate suggests that N3-based inhibitors could be improved by adding chemical modifications that could facilitate the formation of the catalytic dyad ion pair. |
format | Online Article Text |
id | pubmed-8179461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-81794612021-06-22 A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design Ramos-Guzmán, Carlos A. Ruiz-Pernía, J. Javier Tuñón, Iñaki Chem Sci Chemistry The irreversible inhibition of the main protease of SARS-CoV-2 by a Michael acceptor known as N3 has been investigated using multiscale methods. The noncovalent enzyme–inhibitor complex was simulated using classical molecular dynamics techniques and the pose of the inhibitor in the active site was compared to that of the natural substrate, a peptide containing the Gln–Ser scissile bond. The formation of the covalent enzyme–inhibitor complex was then simulated using hybrid QM/MM free energy methods. After binding, the reaction mechanism was found to be composed of two steps: (i) the activation of the catalytic dyad (Cys145 and His41) to form an ion pair and (ii) a Michael addition where the attack of the Sγ atom of Cys145 to the Cβ atom of the inhibitor precedes the water-mediated proton transfer from His41 to the Cα atom. The microscopic description of protease inhibition by N3 obtained from our simulations is strongly supported by the excellent agreement between the estimated activation free energy and the value derived from kinetic experiments. Comparison with the acylation reaction of a peptide substrate suggests that N3-based inhibitors could be improved by adding chemical modifications that could facilitate the formation of the catalytic dyad ion pair. The Royal Society of Chemistry 2021-01-29 /pmc/articles/PMC8179461/ /pubmed/34163622 http://dx.doi.org/10.1039/d0sc04978f Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Ramos-Guzmán, Carlos A. Ruiz-Pernía, J. Javier Tuñón, Iñaki A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design |
title | A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design |
title_full | A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design |
title_fullStr | A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design |
title_full_unstemmed | A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design |
title_short | A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design |
title_sort | microscopic description of sars-cov-2 main protease inhibition with michael acceptors. strategies for improving inhibitor design |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179461/ https://www.ncbi.nlm.nih.gov/pubmed/34163622 http://dx.doi.org/10.1039/d0sc04978f |
work_keys_str_mv | AT ramosguzmancarlosa amicroscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign AT ruizperniajjavier amicroscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign AT tunoninaki amicroscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign AT ramosguzmancarlosa microscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign AT ruizperniajjavier microscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign AT tunoninaki microscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign |